Table 3 Hematologic and organ responses... | American Society of Hematology

Table 3

Hematologic and organ responses

	n	≥ PR	CR	Organ response
All patients*	36†	20 (55%)	3 (8%)	8 (22%)
Phase 2	23†	11 (48%)	2 (9%)	6 (26%)
Evaluable for response (at least 2 cycles of RdC)	32	20 (63%)	3 (9%)	8 (25%)
At DLT (lenalidomide 15 mg/day)	26†	13 (50%)	2 (8%)	5 (19%)
Previously Untreated	24	13 (54%)	2 (8%)	3 (13%)
Pretreated	12†	7 (58%)	1 (8%)	5 (42%)

	n	≥ PR	CR	Organ response
All patients*	36†	20 (55%)	3 (8%)	8 (22%)
Phase 2	23†	11 (48%)	2 (9%)	6 (26%)
Evaluable for response (at least 2 cycles of RdC)	32	20 (63%)	3 (9%)	8 (25%)
At DLT (lenalidomide 15 mg/day)	26†	13 (50%)	2 (8%)	5 (19%)
Previously Untreated	24	13 (54%)	2 (8%)	3 (13%)
Pretreated	12†	7 (58%)	1 (8%)	5 (42%)

PR indicates partial response; and CR, complete remission.

Intention to treat.

One patients withdrew consent after a few days of RdC and was not included in the efficacy analysis.